Plasminogen Activators and Ischemic Stroke: Conditions for Acute Delivery

Gregory J. del Zoppo

doi:10.1055/s-0033-1338126

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2013; 39(04): 406-425
DOI: 10.1055/s-0033-1338126

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Plasminogen Activators and Ischemic Stroke: Conditions for Acute Delivery

Gregory J. del Zoppo

¹Division of Hematology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington

²Department of Neurology, University of Washington School of Medicine, Seattle, Washington

› Author Affiliations

Abstract

Appropriate acute treatment with plasminogen activators (PAs) can significantly increase the probability of minimal or no disability in selected ischemic stroke patients. There is a great deal of evidence showing that intravenous recombinant tissue PAs (rt-PA) infusion accomplishes this goal, recanalization with other PAs has also been demonstrated in the development of this treatment. Recanalization of symptomatic, documented carotid or vertebrobasilar arterial territory occlusions have also been achieved by local intra-arterial PA delivery, although only a single prospective double-blinded randomized placebo-controlled study has been reported. The increase in intracerebral hemorrhage with these agents by either delivery approach underscores the need for careful patient selection, dose-appropriate safety and efficacy, proper clinical trial design, and an understanding of the evolution of cerebral tissue injury due to focal ischemia. Principles underlying the evolution of focal ischemia have been expanded by experience with acute PA intervention. Several questions remain open that concern the manner in which PAs can be applied acutely in ischemic stroke and how injury development can be limited.

Keywords

stroke - plasminogen activators - acute intervention - thrombolysis - hemorrhage - intra-arterial - intravenous - thrombosis

Full Text

References

References
1 Mohr JP, Caplan LR, Melski JW , et al. The Harvard Cooperative Stroke Registry: a prospective registry of patients hospitalized with stroke. Neurology 1978; 28 (8) 754-762
2 Mohr JP, Barnett HJM. Classification of ischemic strokes. In: Barnett HJM, Stein BM, Mohr JP, Yatsu FM, , eds. Stroke: Pathophysiology, Diagnosis and Management, Vol. 1. New York: Churchill Livingstone; 1986: 281-291
3 Solis OJ, Roberson GR, Taveras JM, Mohr J, Pessin MS. Cerebral angiography in acute cerebral infarction. Rev Interam Radiol 1977; 2 (1) 19-25
4 Fieschi C, Argentino C, Lenzi GL, Sacchetti ML, Toni D, Bozzao L. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci 1989; 91 (3) 311-321
5 The National Institutes of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587
6 del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 1998; 29: 4-11
7 Irino T, Taneda M, Minami T. Angiographic manifestations in postrecanalized cerebral infarction. Neurology 1977; 27 (5) 471-475
8 del Zoppo GJ, Poeck K, Pessin MS , et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992; 32 (1) 78-86
9 Fieschi C, Bozzao L. Transient embolic occlusion of the middle cerebral and internal carotid arteries in cerebral apoplexy. J Neurol Neurosurg Psychiatry 1969; 32 (3) 236-240
10 DeWood MA, Spores J, Notske R , et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303 (16) 897-902
11 Kligman AM. Long-term anticoagulant therapy after myocardial infarction. A study of 747 patients in 15 hospitals. JAMA 1965; 193: 929-934
12 Harvald B, Hilden T, Lund E. Long-term anticoagulant therapy after myocardial infarction. Lancet 1962; 2 (7257) 626-630
13 Loeliger EA, Hensen A, Kroes F , et al. A double-blind trial of long-term anticoagulant treatment after myocardial infarction. Acta Med Scand 1967; 182 (5) 549-566
14 Breddin K, Loew D, Lechner K, Oberla K, Walter E. The German-Austrian Aspirin Trial: a comparison of acetylsalicyclic acid, placebo, and phenprocoumon in secondary prevention of myocardial infarction. Circulation 1980; 62 (Suppl): V63-V72
15 Report of the Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980; 2 (8202) 989-994
16 Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323 (3) 147-152
17 Sage JI, Van Uitert RL. Risk of recurrent stroke in patients with atrial fibrillation and non-valvular heart disease. Stroke 1983; 14 (4) 537-540
18 Hart RG, Coull BM, Hart D. Early recurrent embolism associated with nonvalvular atrial fibrillation: a retrospective study. Stroke 1983; 14 (5) 688-693
19 del Zoppo GJ. Prevention and treatment of acute stroke. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, , eds. Hemostasis and Thrombosis. 5th ed. Philadelphia: Lippincott, Williams & Wilkins; 2006: 1477-1496
20 Mundall J, Quintero P, Von Kaulla KN, Harmon R, Austin J. Transient monocular blindness and increased platelet aggregability treated with aspirin. A case report. Neurology 1972; 22 (3) 280-285
21 Harrison MJG, Marshall J, Meadows JC, Russell RW. Effect of aspirin in amaurosis fugax. Lancet 1971; 2 (7727) 743-744
22 Dyken ML, Kolar OJ, Jones FH. Differences in the occurrence of carotid transient ischemic attacks associated with antiplatelet aggregation therapy. Stroke 1973; 4 (5) 732-736
23 Marshall J. The natural history of transient ischemic cerebrovascular attacks. Q J Med 1964; 33: 309-324
24 Wolf PA, Kannel WB, McGee DL, Meeks SL, Bharucha NE, McNamara PM. Duration of atrial fibrillation and imminence of stroke: the Framingham study. Stroke 1983; 14 (5) 664-667
25 Whisnant JP, Matsumoto N, Elveback LR. Transient cerebral ischemic attacks in a community. Rochester, Minnesota, 1955 through 1969. Mayo Clin Proc 1973; 48 (3) 194-198
26 Caplan LR. Are terms such as completed stroke or RIND of continued usefulness?. Stroke 1983; 14 (3) 431-433
27 Johnston SC, Rothwell PM, Nguyen-Huynh MN , et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 2007; 369 (9558) 283-292
28 UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. Br Med J (Clin Res Ed) 1988; 296 (6618) 316-320
29 Denny-Brown D. Recurrent cerebrovascular episodes. Arch Neurol 1960; 2: 194-210
30 Russell RWR. Atheromatous retinal embolism. Lancet 1963; 2 (7322) 1354-1356
31 Hollenhorst RW. Vascular status of patients who have cholesterol emboli in the retina. Am J Ophthalmol 1966; 61 (5 Pt 2) 1159-1165
32 Barnett HJ. The pathophysiology of transient cerebral ischemic attacks. Med Clin North Am 1979; 63 (4) 649-679
33 Marshall J. The Management of Cerebrovascular Diseases. Oxford, England: Blackwell Scientific Publications; 1976
34 Dougherty JH, Levy DE, Weksler BB. Platelet activation in acute cerebral ischemia. Lancet 1977; 3: 821-824
35 Mettinger KL, Nyman D, Kjellin K-G, Sedén Å, Söderström CE. Factor VIII related antigen, anti-thrombin III, spontaneous platelet aggregation and plasminogen activator in ischemic cerebrovascular disease. J Neurol Sci 1979; 41: 31-38
36 de Boer AC, Turpie AG, Butt RW, Duke RJ, Bloch RF, Genton E. Plasma betathromboglobulin and serum fragment E in acute partial stroke. Br J Haematol 1982; 50 (2) 327-334
37 Cella G, Zahavi J, de Haas HA, Kakkar VV. beta-Thromboglobulin, platelet production time and pletelet function in vascular disease. Br J Haematol 1979; 43 (1) 127-136
38 Feinberg WM, Bruck DC, Ring ME, Corrigan Jr JJ. Hemostatic markers in acute stroke. Stroke 1989; 20 (5) 592-597
39 van Kooten F, Ciabattoni G, Patrono C, Schmitz PI, van Gijn J, Koudstaal PJ. Evidence for episodic platelet activation in acute ischemic stroke. Stroke 1994; 25 (2) 278-281
40 Feinberg WM, Pearce LA, Hart RG , et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke 1999; 30 (12) 2547-2553
41 Fisher M, Zipser R. Increased excretion of immunoreactive thromboxane B2 in cerebral ischemia. Stroke 1985; 16 (1) 10-14
42 van Kooten F, Ciabattoni G, Koudstaal PJ, Dippel DW, Patrono C. Increased platelet activation in the chronic phase after cerebral ischemia and intracerebral hemorrhage. Stroke 1999; 30 (3) 546-549
43 Shah AB, Beamer N, Coull BM. Enhanced in vivo platelet activation in subtypes of ischemic stroke. Stroke 1985; 16 (4) 643-647
44 Iwamoto T, Kubo H, Takasaki M. Platelet activation in the cerebral circulation in different subtypes of ischemic stroke and Binswanger's disease. Stroke 1995; 26 (1) 52-56
45 Del Zoppo GJ, Copeland BR, Harker LA , et al. Experimental acute thrombotic stroke in baboons. Stroke 1986; 17 (6) 1254-1265
46 Abumiya T, Fitridge R, Mazur C , et al. Integrin alpha(IIb)beta(3) inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. Stroke 2000; 31 (6) 1402-1409 , discussion 1409–1410
47 del Zoppo GJ, Schmid-Schönbein GW, Mori E, Copeland BR, Chang CM. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke 1991; 22 (10) 1276-1283
48 Garcia JH, Liu KF, Yoshida Y, Lian J, Chen S, del Zoppo GJ. Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat). Am J Pathol 1994; 144 (1) 188-199
49 Okada Y, Copeland BR, Fitridge R, Koziol JA, del Zoppo GJ. Fibrin contributes to microvascular obstructions and parenchymal changes during early focal cerebral ischemia and reperfusion. Stroke 1994; 25 (9) 1847-1853 , discussion 1853–1854
50 Choudhri TF, Hoh BL, Zerwes HG , et al. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. J Clin Invest 1998; 102 (7) 1301-1310
51 Gent M, Blakely JA, Easton JD , et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1 (8649) 1215-1220
52 Britton M, Helmers C, Samuelsson K. A Swedish Cooperative Study. High-dose acetylsalicylic acid after cerebral infarction. Stroke 1987; 18: 325-334
53 Gent M, Blakely JA, Hachinski V , et al. A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke. Stroke 1985; 16 (3) 416-424
54 Scmidt EV, Smirnov VE, Ryabova VS. Results of the seven-year prospective study of stroke patients. Stroke 1988; 19 (8) 942-949
55 Wityk RJ, Pessin MS, Kaplan RF, Caplan LR. Serial assessment of acute stroke using the NIH Stroke Scale. Stroke 1994; 25 (2) 362-365
56 Holroyd-Leduc JM, Kapral MK, Austin PC, Tu JV. Sex differences and similarities in the management and outcome of stroke patients. Stroke 2000; 31 (8) 1833-1837
57 Hurn PD, Macrae IM. Estrogen as a neuroprotectant in stroke. J Cereb Blood Flow Metab 2000; 20 (4) 631-652
58 McCullough LD, Alkayed NJ, Traystman RJ, Williams MJ, Hurn PD. Postischemic estrogen reduces hypoperfusion and secondary ischemia after experimental stroke. Stroke 2001; 32 (3) 796-802
59 Silver FL, Norris JW, Lewis AJ, Hachinski VC. Early mortality following stroke: a prospective review. Stroke 1984; 15 (3) 492-496
60 Shaw C-M, Alvord Jr EC, Berry RG. Swelling of the brain following ischemic infarction with arterial occlusion. Arch Neurol 1959; 1: 161-177
61 Spetzler RF, Selman WR, Weinstein P , et al. Chronic reversible cerebral ischemia: evaluation of a new baboon model. Neurosurgery 1980; 7 (3) 257-261
62 Bogousslavsky J, Van Melle G, Regli F. The Lausanne Stroke Registry: analysis of 1,000 consecutive patients with first stroke. Stroke 1988; 19 (9) 1083-1092
63 Foulkes MA, Wolf PA, Price TR, Mohr JP, Hier DB. The Stroke Data Bank: design, methods, and baseline characteristics. Stroke 1988; 19 (5) 547-554
64 International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997; 349 (9065) 1569-1581
65 Chen ZM, Sandercock P, Pan HC , et al. Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 2000; 31 (6) 1240-1249
66 Hacke W, Kaste M, Fieschi C , et al; The European Cooperative Acute Stroke Study (ECASS). Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 1995; 274 (13) 1017-1025
67 del Zoppo GJ. Acute stroke—on the threshold of a therapy?. N Engl J Med 1995; 333 (24) 1632-1633
68 Fisher CM, Adams RD. Observations on brain embolism with special reference to hemorrhage infarction. In: Furlan AJ, , ed. The Heart and Stroke. Exploring Mutual Cerebrovascular and Cardiovascular Issues. 1st ed. New York: Springer-Verlag; 1987: 17-36
69 Fisher M, Adams RD. Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction. J Neuropathol Exp Neurol 1951; 10 (1) 92-94
70 Jörgensen L, Torvik A. Ischaemic cerebrovascular diseases in an autopsy series. 2. Prevalence, location, pathogenesis, and clinical course of cerebral infarcts. J Neurol Sci 1969; 9 (2) 285-320
71 Kwa VI, Franke CL, Verbeeten Jr B, Stam J. Amsterdam Vascular Medicine Group. Silent intracerebral microhemorrhages in patients with ischemic stroke. Ann Neurol 1998; 44 (3) 372-377
72 Okada Y, Yamaguchi T, Minematsu K , et al. Hemorrhagic transformation in cerebral embolism. Stroke 1989; 20 (5) 598-603
73 Hornig CR, Dorndorf W, Agnoli AL. Hemorrhagic cerebral infarction—a prospective study. Stroke 1986; 17 (2) 179-185
74 Yamaguchi T, Minematsu K, Choki J, Ikeda M. Clinical and neuroradiological analysis of thrombotic and embolic cerebral infarction. Jpn Circ J 1984; 48 (1) 50-58
75 Hamann GF, Okada Y, Fitridge R, del Zoppo GJ. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke 1995; 26 (11) 2120-2126
76 Hamann GF, Okada Y, del Zoppo GJ. Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cereb Blood Flow Metab 1996; 16 (6) 1373-1378
77 Pessin MS, Teal PA, Caplan LR. Hemorrhagic infarction: guilt by association?. AJNR Am J Neuroradiol 1991; 12 (6) 1123-1126
78 Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: brain hemorrhage and management options. Stroke 1984; 15 (5) 779-789
79 Babikian VL, Kase CS, Pessin MS, Norrving B, Gorelick PB. Intracerebral hemorrhage in stroke patients anticoagulated with heparin. Stroke 1989; 20 (11) 1500-1503
80 Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119 (1, Suppl): 108S-121S
81 Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143 (1-2) 1-13
82 Baron JC, von Kummer R, del Zoppo GJ. Treatment of acute ischemic stroke. Challenging the concept of a rigid and universal time window. (Editorial) Stroke 1995; 26 (12) 2219-2221
83 von Kummer R, Meyding-Lamadé U, Forsting M , et al. Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk. AJNR Am J Neuroradiol 1994; 15 (1) 9-15 , discussion 16–18
84 Warach S, Gaa J, Siewert B, Wielopolski P, Edelman RR. Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging. Ann Neurol 1995; 37 (2) 231-241
85 Garcia JH, Liu KF, Ho KL. Neuronal necrosis after middle cerebral artery occlusion in Wistar rats progresses at different time intervals in the caudoputamen and the cortex. Stroke 1995; 26 (4) 636-642 , discussion 643
86 Tagaya M, Liu KF, Copeland B , et al. DNA scission after focal brain ischemia. Temporal differences in two species. Stroke 1997; 28 (6) 1245-1254
87 Astrup J, Siesjö BK, Symon L. Thresholds in cerebral ischemia - the ischemic penumbra. Stroke 1981; 12 (6) 723-725
88 Branston NM, Symon L, Crockard HA, Pasztor E. Relationship between the cortical evoked potential and local cortical blood flow following acute middle cerebral artery occlusion in the baboon. Exp Neurol 1974; 45 (2) 195-208
89 Astrup J, Symon L, Branston NM, Lassen NA. Cortical evoked potential and extracellular K+ and H+ at critical levels of brain ischemia. Stroke 1977; 8 (1) 51-57
90 Branston NM, Strong AJ, Symon L. Extracellular potassium activity, evoked potential and tissue blood flow. Relationships during progressive ischaemia in baboon cerebral cortex. J Neurol Sci 1977; 32 (3) 305-321
91 del Zoppo GJ, Sharp FR, Heiss W-D, Albers GW. Heterogeneity in the penumbra. J Cereb Blood Flow Metab 2011; 31 (9) 1836-1851
92 Albers GW, Thijs VN, Wechsler L , et al; DEFUSE Investigators. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006; 60 (5) 508-517
93 Olivot JM, Mlynash M, Thijs VN , et al. Relationships between cerebral perfusion and reversibility of acute diffusion lesions in DEFUSE: insights from RADAR. Stroke 2009; 40 (5) 1692-1697
94 Heiss WD. Ischemic penumbra: evidence from functional imaging in man. J Cereb Blood Flow Metab 2000; 20 (9) 1276-1293
95 Zülch K-J. The Cerebral Infarct: Pathology, Pathogenesis, and Computed Tomography. 1st ed. Berlin: Springer-Verlag; 1985
96 Bär T. Morphometric evaluation of capillaries in different laminae of rat cerebral cortex by automatic image analysis: Changes during development and aging. In: Cervos-Navarro J, , ed.; Advances in Neurology. 20th ed. New York: Raven Press; 1978: 1-9
97 Bär T. The vascular system of the cerebral cortex. Adv Anat Embryol Cell Biol 1980; 59: I-VI , 1–62
98 Russell RWR. Observations on the retinal blood-vessels in monocular blindness. Lancet 1961; 2 (7218) 1422-1428
99 Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. Stroke 1977; 8 (3) 301-314
100 The Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978; 299 (2) 53-59
101 Bousser MG, Eschwege E, Haguenau M , et al. “AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983; 14 (1) 5-14
102 The ESPS Group. The European Stroke Prevention Study (ESPS). Principal end-points. Lancet 1987; 2 (8572) 1351-1354
103 ESPS-2 Working Group. Second European Stroke Prevention Study. ESPS-2 Working Group. J Neurol 1992; 239 (6) 299-301
104 Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367 (9523) 1665-1673
105 Hass WK, Easton JD, Adams Jr HP , et al; Ticlopidine Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321 (8) 501-507
106 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348 (9038) 1329-1339
107 Diener H-C, Bogousslavsky J, Brass LM , et al; MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364 (9431) 331-337
108 Bhatt DL, Fox KA, Hacke W , et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354 (16) 1706-1717
109 Campbell MH. Basilar artery syndrome. Can Med Assoc J 1953; 69 (3) 314-315
110 Millikan CH, Siekert RG, Shick RM. Studies in cerebrovascular disease. III. The use of anticoagulant drugs in the treatment of insufficiency or thrombosis within the basilar arterial system. Proc Staff Meet Mayo Clin 1955; 30 (6) 116-126
111 Baker RN, Broward JA, Fang HC , et al. Anticoagulant therapy in cerebral infarction. Report on cooperative study. Neurology 1962; 12: 823-835
112 Baker RN, Ramseyer JC, Schwartz WS. Prognosis in patients with transient cerebral ischemic attacks. Neurology 1968; 18: 1157-1165
113 Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: a randomized trial. Stroke 1983; 14 (5) 668-676
114 Albers GW. Antithrombotic agents in cerebral ischemia. Am J Cardiol 1995; 75 (6) 34B-38B
115 Mohr JP, Thompson JLP, Lazar RM , et al; Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345 (20) 1444-1451
116 Fisher CM. Anticoagulant therapy in cerebral thrombosis and cerebral embolism. A national cooperative study, interim report. Neurology 1961; 11 (4) 119-131
117 Hill AB, Marshall J, Shaw DA. Cerebrovascular disease: trial of long-term anticoagulant therapy. BMJ 1962; 2 (5311) 1003-1006
118 McDowell F, McDevitt E. Treatment of the completed stroke with long-term anticoagulant. Six and one-half years' experience. In: Siekert RH, Whisnant JR, , eds. Cerebral Vascular Diseases, Fourth Princeton Conference. New York, NY: Grune & Stratton; 1965: 185-199
119 Enger E, Boyesen S. Long-term anticoagulant therapy in patients with cerebral infarction: a controlled clinical study. Acta Med Scand 1965; 179 (Suppl): 1-61
120 Baker RN. An evaluation of anticoagulant therapy in the treatment of cerebrovascular disease. Report of the Veterans Administration Cooperative Study of Atherosclerosis, Neruology Section. Neurology 1961; 11 (4) 132-138
121 CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997; 349 (9066) 1641-1649
122 Chen ZM, Xie JX, Peto R , et al. Chinese Acute Stroke Trial (CAST): rationale, design and progress. Cerebrovasc Dis 1996; 6: 23
123 Kay R, Wong KS, Yu YL , et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995; 333 (24) 1588-1593
124 Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 2000; 355 (9211) 1205-1210
125 Diener HC, Ringelstein EB, von Kummer R , et al; Therapy of Patients With Acute Stroke (TOPAS) Investigators. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Stroke 2001; 32 (1) 22-29
126 Bath PM, Lindenstrom E, Boysen G , et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet 2001; 358 (9283) 702-710
127 Stutzmann JM, Mary V, Wahl F, Grosjean-Piot O, Uzan A, Pratt J. Neuroprotective profile of enoxaparin, a low molecular weight heparin, in in vivo models of cerebral ischemia or traumatic brain injury in rats: a review. CNS Drug Rev 2002; 8 (1) 1-30
128 Liu M, Counsell C, Sandercock P. Anticoagulants for preventing recurrence following ischaemic stroke or transient ischaemic attack. Cochrane Database Syst Rev 2000; (2) CD000248
129 Gubitz G, Counsell C, Sandercock P, Signorini D. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev 2000; (2) CD000024
130 Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1 (8631) 175-179
131 Stroke Prevention in Atrial Fibrillation Study Group Investigators. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med 1990; 322 (12) 863-868
132 The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323 (22) 1505-1511
133 Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348 (9028) 633-638
134 The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA 1998; 279: 1265-1272
135 EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342 (8882) 1255-1262
136 The Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. Arch Intern Med 1997; 157 (11) 1237-1240
137 Connolly SJ, Ezekowitz MD, Yusuf S , et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
138 Patel MR, Mahaffey KW, Garg J , et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
139 del Zoppo GJ, Eliasziw M. New options in anticoagulation for atrial fibrillation. N Engl J Med 2011; 365 (10) 952-953
140 Connolly SJ, Eikelboom J, Joyner C , et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364 (9) 806-817
141 Granger CB, Alexander JH, McMurray JJ , et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
142 Coulshed N, Epstein EJ, McKendrick CS, Galloway RW, Walker E. Systemic embolism in mitral valve disease. Br Heart J 1970; 32 (1) 26-34
143 Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. BMJ 1964; 1 (5392) 1209-1212
144 Daley R, Mattingly TW, Holt CL, Bland EF, White PD. Systemic arterial embolism in rheumatic heart disease. Am Heart J 1951; 42 (4) 566-581
145 Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333 (1) 11-17
146 Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001; 119 (1, Suppl): 220S-227S
147 Horstkotte D, Schulte H, Bircks W, Strauer B. Unexpected findings concerning thromboembolic complications and anticoagulation after complete 10. year follow up of patients with St. Jude Medical prostheses. J Heart Valve Dis 1993; 2 (3) 291-301
148 Horstkotte D, Scharf RE, Schultheiss HP. Intracardiac thrombosis: patient-related and device-related factors. J Heart Valve Dis 1995; 4 (2) 114-120
149 Levine HJ, Pauker SG, Salzman EW. Antithrombotic therapy in valvular heart disease. Chest 1989; 95 (2, Suppl): 98S-106S
150 Stein PD, Kantrowitz A. Antithrombotic therapy in mechanical and biological prosthetic heart valves and saphenous vein bypass grafts. Chest 1989; 95 (2, Suppl): 107S-117S
151 Horstkotte D, Schulte HD, Bircks W, Strauer BE. Lower intensity anticoagulation therapy results in lower complication rates with the St. Jude Medical prosthesis. J Thorac Cardiovasc Surg 1994; 107 (4) 1136-1145
152 Stein PD, Grandison D, Hua TA , et al. Therapeutic level of oral anticoagulation with warfarin in patients with mechanical prosthetic heart valves: review of literature and recommendations based on international normalized ratio. Postgrad Med J 1994; 70 (Suppl. 01) S72-S83
153 Dale J, Myhre E, Storstein O, Stormorken H, Efskind L. Prevention of arterial thromboembolism with acetylsalicylic acid. A controlled clinical study in patients with aortic ball valves. Am Heart J 1977; 94 (1) 101-111
154 Altman R, Boullon F, Rouvier J, Raca R, de la Fuente L, Favaloro R. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thorac Cardiovasc Surg 1976; 72 (1) 127-129
155 Sullivan JM, Harken DE, Gorlin R. Effect of dipyridamole on the incidence of arterial emboli after cardiac valve replacement. Circulation 1969; 39 (5) (Suppl. 01) I149-I153
156 Sullivan JM, Harken DE, Gorlin R. Pharmacologic control of thromboembolic complications of cardiac-valve replacement. N Engl J Med 1971; 284 (25) 1391-1394
157 Altman R, Rouvier J, Gurfinkel E, Scazziota A, Turpie AG. Comparison of high-dose with low-dose aspirin in patients with mechanical heart valve replacement treated with oral anticoagulant. Circulation 1996; 94 (9) 2113-2116
158 Kontozis L, Skudicky D, Hopley MJ, Sareli P. Long-term follow-up of St. Jude Medical prosthesis in a young rheumatic population using low-level warfarin anticoagulation: an analysis of the temporal distribution of causes of death. Am J Cardiol 1998; 81 (6) 736-739
159 Chesebro JH, Fuster V, Elveback LR , et al. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol 1983; 51 (9) 1537-1541
160 Pouleur H, Buyse M. Effects of dipyridamole in combination with anticoagulant therapy on survival and thromboembolic events in patients with prosthetic heart valves. A meta-analysis of the randomized trials. J Thorac Cardiovasc Surg 1995; 110 (2) 463-472
161 Massel D, Little SH. Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis. Am Coll Cardiol 2001; 37: 569-578
162 Oyer PE, Stinson EB, Griepp RB, Shumway NE. Valve replacement with the Starr-Edwards and Hancock prostheses: comparative analysis of late morbidity and mortality. Ann Surg 1977; 186 (3) 301-309
163 Ionescu MI, Smith DR, Hasan SS, Chidambaram M, Tandon AP. Clinical durability of the pericardial xenograft valve: ten years experience with mitral replacement. Ann Thorac Surg 1982; 34 (3) 265-277
164 Williams JB, Karp RB, Kirklin JW , et al. Considerations in selection and management of patients undergoing valve replacement with glutaraldehyde-fixed porcine bioprotheses. Ann Thorac Surg 1980; 30 (3) 247-258
165 Cohn LH, Allred EN, DiSesa VJ, Sawtelle K, Shemin RJ, Collins Jr JJ. Early and late risk of aortic valve replacement. A 12. year concomitant comparison of the porcine bioprosthetic and tilting disc prosthetic aortic valves. J Thorac Cardiovasc Surg 1984; 88 (5 Pt 1) 695-705
166 Kelton JG. Antiplatelet agents: rationale and results. Clin Haematol 1983; 12 (1) 311-354
167 Nuñez L, Aguado MG, Celemín D, Iglesias A, Larrea JL. Aspirin or Coumadin as the drug of choice for valve replacement with porcine bioprosthesis. Ann Thorac Surg 1982; 33 (4) 354-358
168 Nuñez L, Gil Aguado M, Larrea JL, Celemín D, Oliver J. Prevention of thromboembolism using aspirin after mitral valve replacement with porcine bioprosthesis. Ann Thorac Surg 1984; 37 (1) 84-87
169 Breddin K, Loew D, Lechner K, Uberla K, Walter E. Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Haemostasis 1980; 9 (6) 325-344
170 Hurlen M, Smith P, Arnesen H. Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. The WARIS-II (Warfarin-Aspirin Reinfarction Study) design. Scand Cardiovasc J 2000; 34 (2) 168-171
171 Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347 (13) 969-974
172 Hurlen M, Eikvar L, Seljeflot I, Arnesen H. Occult bleeding in three different antithrombotic regimes after myocardial infarction. A WARIS-II subgroup analysis. Thromb Res 2006; 118 (4) 433-438
173 Meyer JS, Herndon RM, Gotoh F, Tazaki Y, Nelson JN, Johnson JF. Therapeutic thrombolysis. In: Millikan CH, Siekert RG, Whisnant JP, , eds. Cerebral Vascular Diseases, Third Princeton Conference. New York: Grune and Stratton; 1961: 160-177
174 Sherry S. Historical developments in fibrinolysis. In: Sawaya R, , ed. Fibrinolysis and the Central Nervous System. Philadelphia: Hanley & Belfus, Inc.; 1990: 3-13
175 Abe T, Kazawa M, Naito I , et al. Clinical effect of urokinase (60,000 units/day) on cerebral infarction–Comparative study by means of multiple center double-blind test. Blood Vessels 1981; 12: 342-358
176 Abe T, Kazama M, Naito I , et al. Clinical evaluation for efficacy of tissue culture urokinase (TCUK) on cerebral thrombosis by means of multicenter double-blind study. Blood Vessels 1981; 12: 321-341
177 Fletcher AP, Alkjaersig N, Lewis M , et al. A pilot study of urokinase therapy in cerebral infarction. Stroke 1976; 7 (2) 135-142
178 Del Zoppo GJ, Zeumer H, Harker LA. Thrombolytic therapy in stroke: possibilities and hazards. Stroke 1986; 17 (4) 595-607
179 Atarashi J, Otomo E, Araki G , et al. Clinical utility of urokinase in the treatment of acute stage of cerebral thrombosis: multi-center double-blind study in comparison with placebo. Clin Eval 1985; 13: 659-709
180 Otomo E, Araki G, Itoh E , et al. Clinical efficacy of urokinase in the treatment of cerebral thrombosis. Clin Eval 1985; 13: 711-751
181 Abe T, Terashi A, Tohgi H, Sasoh S, Naito I. Clinical efficacy of intravenous administration of SM-9527 (t-PA) in cerebral thrombosis. Clin Eval 1990; 18: 39-69
182 Otomo E, Tohgi H, Hirai S , et al. Clinical efficacy of AK-124 (tissue plasminogen activator) in the treatment of cerebral thrombosis: study by means of multicenter double-blind comparison with urokinase. Yakuri To Chiryo 1988; 16: 3775-3821
183 Baron JC. Perfusion thresholds in human cerebral ischemia: historical perspective and therapeutic implications. Cerebrovasc Dis 2001; 11 (Suppl. 01) 2-8
184 Mori E, Tabuchi M, Yoshida T, Yamadori A. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke 1988; 19 (7) 802-812
185 del Zoppo GJ, Ferbert A, Otis S , et al. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke. A pilot study. Stroke 1988; 19 (3) 307-313
186 Matsumoto K, Satoh K. Topical intraarterial urokinase infusion for acute stroke. In: Hacke W, del Zoppo GJ, Hirschberg M, , eds. Thrombolytic Therapy in Acute Ischemic Stroke. Heidelberg, Germany: Springer-Verlag; 1991: 207-212
187 Mori E, Yoneda Y, Tabuchi M , et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42 (5) 976-982
188 Yamaguchi T. Intravenous rt-PA in acute embolic stroke. In: Hacke W, del Zoppo GJ, Hirschberg M, , eds. Thrombolytic Therapy in Acute Ischemic Stroke. Heidelberg, Germany: Springer-Verlag; 1991: 168-174
189 von Kummer R, Forsting M, Sartor K, Hacke W. Intravenous recombinant tissue plasminogen activator in acute stroke. In: Hacke W, del Zoppo GJ, Hirschberg M, , eds. Thrombolytic Therapy in Acute Ischemic Stroke. Heidelberg, Germany: Springer-Verlag; 1991: 161-167
190 del Zoppo GJ. Thrombolysis: New concepts in the treatment of stroke. In: Hennerici M, Sitzer G, Weger H-D, , eds. Carotid Artery Plaques. Karger: Basel; 1988: 247-272
191 Hommel M, Boissel JP, Cornu C , et al. Termination of trial of streptokinase in severe acute ischemic stroke. Lancet 1995; 345: 578-579
192 Donnan GA, Davis SM, Chambers BR , et al. Trials of streptokinase in severe acute ischaemic stroke. Lancet 1995; 345 (8949) 578-579
193 Multicenter Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial—Italy (MAST-I) Group. Lancet 1995; 346 (8989) 1509-1514
194 Kwiatkowski TG, Libman RB, Frankel M , et al; National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 1999; 340 (23) 1781-1787
195 Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000; 283 (9) 1145-1150
196 Hacke W, Kaste M, Fieschi C , et al; Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352 (9136) 1245-1251
197 von Kummer R, Allen KL, Holle R , et al. Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology 1997; 205 (2) 327-333
198 Wahlgren N, Ahmed N, Dávalos A , et al; SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369 (9558) 275-282
199 Wahlgren N, Ahmed N, Dávalos A , et al; SITS investigators. Thrombolysis with alteplase 3-4.5. h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008; 372 (9646) 1303-1309
200 Hacke W, Kaste M, Bluhmki E , et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359 (13) 1317-1329
201 Hacke W, Kaste M, Fieschi C , et al; Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352 (9136) 1245-1251
202 Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke 2000; 31 (4) 811-816
203 Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282 (21) 2019-2026
204 Del Zoppo GJ, Saver JL, Jauch EC, Adams Jr HP. American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009; 40 (8) 2945-2948
205 Yamaguchi T, Hayakawa T, Kikuchi H. for the Japanese Thrombolysis Study Group. Intravenous tissue plasminogen activator in acute thromboembolic stroke: A placebo-controlled, double-blind trial. In: del Zoppo GJ, Mori E, Hacke W, , eds. Thrombolytic Therapy in Acute Ischemic Stroke II. Heidelberg, Germany: Springer-Verlag; 1993: 59-65
206 Hacke W, Donnan G, Fieschi C , et al; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363 (9411) 768-774
207 Levy DE, Brott TG, Haley Jr EC , et al. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke 1994; 25 (2) 291-297
208 Larrue V, von Kummer R, del Zoppo GJ, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997; 28 (5) 957-960
209 Larrue V, von Kummer R R, Müller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001; 32 (2) 438-441
210 Dubey N, Bakshi R, Wasay M, Dmochowski J. Early computed tomography hypodensity predicts hemorrhage after intravenous tissue plasminogen activator in acute ischemic stroke. J Neuroimaging 2001; 11 (2) 184-188
211 Kalafut MA, Schriger DL, Saver JL, Starkman S. Detection of early CT signs of >1/3 middle cerebral artery infarctions : interrater reliability and sensitivity of CT interpretation by physicians involved in acute stroke care. Stroke 2000; 31 (7) 1667-1671
212 Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2009; (4) CD000213
213 Haley Jr EC, Lyden PD, Johnston KC, Hemmen TM. TNK in Stroke Investigators. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 2005; 36 (3) 607-612
214 Parsons M, Spratt N, Bivard A , et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012; 366 (12) 1099-1107
215 Hacke W, Albers G, Al-Rawi Y , et al; DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36 (1) 66-73
216 Furlan AJ, Eyding D, Albers GW , et al; DEDAS Investigators. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006; 37 (5) 1227-1231
217 Hacke W, Furlan AJ, Al-Rawi Y , et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009; 8 (2) 141-150
218 Caplan LR. “Top of the basilar” syndrome. Neurology 1980; 30 (1) 72-79
219 Archer CR, Horenstein S. Basilar artery occlusion: clinical and radiological correlation. Stroke 1977; 8 (3) 383-390
220 Nenci GG, Gresele P, Taramelli M, Agnelli G, Signorini E. Thrombolytic therapy for thromboembolism of vertebrobasilar artery. Angiology 1983; 34 (9) 561-571
221 Hacke W, Zeumer H, Ferbert A, Brückmann H, del Zoppo GJ. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988; 19 (10) 1216-1222
222 Zeumer H, Freitag HJ, Grzyska U, Neunzig HP. Local intraarterial fibrinolysis in acute vertebrobasilar occlusion. Technical developments and recent results. Neuroradiology 1989; 31 (4) 336-340
223 Mobius E, Berg-Dammer E, Kuhne D, Aster HC. Local thrombolytic therapy in acute basilar artery occlusion. In: Hacke W, del Zoppo GJ, Hirschberg M, , eds.; Thrombolytic Therapy in Acute Ischemic Stroke. Berlin, Germany: Springer Verlag; 1991: 213-215
224 Furlan AJ, Higashida R, Wechsler L , et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999; 282 (21) 2003-2011
225 Bell Jr WR, Bells Jr WR. Defibrinogenating enzymes. Drugs 1997; 54 (Suppl. 03) 18-30 , discussion 30–31
226 The Ancrod Stroke Study Investigators. Ancrod for the treatment of acute ischemic brain infarction. Stroke 1994; 25 (9) 1755-1759
227 Krishnamurti C, Barr CF, Hassett MA, Young GD, Alving BM. Plasminogen activator inhibitor: a regulator of ancrod-induced fibrin deposition in rabbits. Blood 1987; 69 (3) 798-803
228 Sherman DG, Atkinson RP, Chippendale T , et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA 2000; 283 (18) 2395-2403
229 Orgogozo JM, Verstraete M, Kay R, Hennerici M, Lenzi GL. Outcomes of ancrod in acute ischemic stroke. Independent Data and Safety Monitoring Board for ESTAT. Steering Committee for ESTAT. European Stroke Treatment with Ancrod Trial. JAMA 2000; 284 (15) 1926-1927
230 Levy DE, del Zoppo GJ, Demaerschalk BM , et al. Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program. Stroke 2009; 40 (12) 3796-3803
231 Borhani Haghighi A, Edgell RC, Cruz-Flores S , et al. Mortality of cerebral venous-sinus thrombosis in a large national sample. Stroke 2012; 43 (1) 262-264
232 Guo XB, Guan S, Fan Y, Song LJ. Local thrombolysis for severe cerebral venous sinus thrombosis. AJNR Am J Neuroradiol 2012; 33 (6) 1187-1190
233 Sidani CA, Ballourah W, El Dassouki M , et al. Venous sinus thrombosis leading to stroke in a patient with sickle cell disease on hydroxyurea and high hemoglobin levels: treatment with thrombolysis. Am J Hematol 2008; 83 (10) 818-820
234 Weatherby SJM, Edwards NC, West R, Heafield MTE. Good outcome in early pregnancy following direct thrombolysis for cerebral venous sinus thrombosis. J Neurol 2003; 250 (11) 1372-1373
235 Yamini B, Loch Macdonald R, Rosenblum J. Treatment of deep cerebral venous thrombosis by local infusion of tissue plasminogen activator. Surg Neurol 2001; 55 (6) 340-346
236 Wasay M, Bakshi R, Kojan S, Bobustuc G, Dubey N, Unwin DH. Nonrandomized comparison of local urokinase thrombolysis versus systemic heparin anticoagulation for superior sagittal sinus thrombosis. Stroke 2001; 32 (10) 2310-2317
237 Wasay M, Dai AI, Ansari M, Shaikh Z, Roach ES. Cerebral venous sinus thrombosis in children: a multicenter cohort from the United States. J Child Neurol 2008; 23 (1) 26-31
238 Anderson DC, Kappelle LJ, Eliasziw M, Babikian VL, Pearce LA, Barnett HJ. Occurrence of hemispheric and retinal ischemia in atrial fibrillation compared with carotid stenosis. Stroke 2002; 33 (8) 1963-1967
239 Bashshur ZF, Taher A, Masri AF, Najjar D, Arayssi TK, Noureddin BN. Anticardiolipin antibodies in patients with retinal vein occlusion and no risk factors: a prospective study. Retina 2003; 23 (4) 486-490
240 Kwaan HC. Thromboembolic disorders of the eye. In: Comerota AC, , ed. Thrombolytic Therapy. Orlando, FL: Grune & Stratton; 1988: 153-163
241 Hattenbach LO, Wellermann G, Steinkamp GW, Scharrer I, Koch FH, Ohrloff C. Visual outcome after treatment with low-dose recombinant tissue plasminogen activator or hemodilution in ischemic central retinal vein occlusion. Ophthalmologica 1999; 213 (6) 360-366
242 Freitag H-J, Zeumer H, Knospe V. Acute central retinal artery occlusion and the role of thrombolysis. In: del Zoppo GJ, Mori E, Hacke W, , eds. Thrombolytic Therapy in Acute Ischemic Stroke II. Heidelberg, Germany: Springer-Verlag; 1993: 103-105
243 Schmidt D, Schumacher M, Wakhloo AK. Microcatheter urokinase infusion in central retinal artery occlusion. Am J Ophthalmol 1992; 113 (4) 429-434
244 Hattenbach LO, Friedrich Arndt C, Lerche R , et al. Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion. Retina 2009; 29 (7) 932-940
245 Costen MT, Donaldson WB, Olson JA. Acute central retinal vein occlusion successfully treated with intravenous thrombolysis. Br J Ophthalmol 1999; 83 (10) 1196-1197
246 Chen CS, Lee AW, Campbell B , et al. Study of the efficacy of intravenous tissue plasminogen activator in central retinal artery occlusion. Int J Stroke 2011; 6 (1) 87-89
247 Hattenbach LO, Puchta J, Hilgenberg I. Experimental endoscopic endovascular cannulation: a novel approach to thrombolysis in retinal vessel occlusion. Invest Ophthalmol Vis Sci 2012; 53 (1) 42-46
248 Schwenn OK, Wüstenberg EG, Konerding MA, Hattenbach LO. Experimental percutaneous cannulation of the supraorbital arteries: implication for future therapy. Invest Ophthalmol Vis Sci 2005; 46 (5) 1557-1560
249 The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med 1989; 320 (10) 618-627
250 Rao AK, Pratt C, Berke A , et al. Thrombolysis in Myocardial Infarction (TIMI) Trial—phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11 (1) 1-11
251 Mori E. Safety and efficacy of 0.6 mg/kg rt-PA: optimum rt-PA dose revisited. Ann N Y Acad Sci 2012; 1268: 108-112
252 Yamaguchi T, Mori E, Minematsu K , et al; Japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006; 37 (7) 1810-1815
253 Nakagawara J, Minematsu K, Okada Y , et al; J-MARS Investigators. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010; 41 (9) 1984-1989
254 Slivka A, Pulsinelli WA. Hemorrhagic complications of thrombolytic therapy in experimental stroke. Stroke 1987; 18: 1148-1156
255 Edvinsson L, MacKenzie ET, McCulloch J. General and comparative anatomy of the cerebral circulation. In: Edvinsson L, MacKenzie ET, McCulloch J, , eds. Cerebral Blood Flow and Metabolism. 1 ed. New York: Raven Press; 1993: 3-39
256 Lansberg MG, Straka M, Kemp S , et al; DEFUSE 2 study investigators. MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. Lancet Neurol 2012; 11 (10) 860-867
257 The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke 2000; 31 (3) 601-609
258 Pancioli AM, Broderick J, Brott T , et al; CLEAR Trial Investigators. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke 2008; 39 (12) 3268-3276
259 Ezekowitz MD, Reilly PA, Nehmiz G , et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007; 100 (9) 1419-1426
260 IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004; 35 (4) 904-911
261 IMS II Trial Investigators. The Interventional Management of Stroke (IMS) II Study. Stroke 2007; 38 (7) 2127-2135
262 Qureshi AI, Hussein HM, Abdelmoula M, Georgiadis AL, Janjua N. Subacute recanalization and reocclusion in patients with acute ischemic stroke following endovascular treatment. Neurocrit Care 2009; 10 (2) 195-203
263 Janjua N, Alkawi A, Suri MF, Qureshi AI. Impact of arterial reocclusion and distal fragmentation during thrombolysis among patients with acute ischemic stroke. AJNR Am J Neuroradiol 2008; 29 (2) 253-258
264 Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002; 59 (6) 862-867
265 Zinkstok SM, Roos YB. ARTIS investigators. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet 2012; 380 (9843) 731-737
266 De Haan R, Horn J, Limburg M, Van Der Meulen J, Bossuyt P. A comparison of five stroke scales with measures of disability, handicap, and quality of life. Stroke 1993; 24 (8) 1178-1181
267 del Zoppo GJ, Koziol JA. Recanalization and stroke outcome. Circulation 2007; 115 (20) 2602-2605